Metoprolol Ratiopharm (Metoprolol Tartrate)

• Metoprolol Ratiopharm, a selective β1‑adrenergic blocker, is used in several cardiovascular conditions.
• Hypertension: reduces systolic and diastolic blood pressure, decreasing cardiovascular risk.
• Angina pectoris: decreases myocardial oxygen demand, relieving chest pain.
• Post‑myocardial infarction: improves survival by reducing arrhythmias and adverse remodeling.
• Chronic heart failure: lowers mortality and hospitalisation by improving cardiac output.
• Rate control in atrial fibrillation: slows ventricular response, helping maintain a regular rhythm.

• Metoprolol Tartrate selectively antagonises β1‑adrenergic receptors located primarily in cardiac tissue. By blocking the effects of endogenous catecholamines, it decreases heart rate, myocardial contractility and conduction velocity, leading to reduced cardiac output and lower arterial pressure. The drug’s cardio‑selectivity limits bronchial β2‑receptor blockade, providing a favourable safety profile compared with non‑selective beta blockers. Consequently, the overall myocardial oxygen consumption falls, contributing to its anti‑ischemic effect.

Metoprolol Ratiopharm may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Fatigue: feeling of tiredness or lack of energy.
• Dizziness: light‑headed sensation, especially when standing quickly.
• Bradycardia: slower than normal heart rate.
• Cold extremities: reduced blood flow to hands and feet.
• Gastrointestinal upset: nausea, abdominal discomfort or diarrhoea.
• Headache: mild to moderate head pain.

Serious or Rare Side Effects

• Severe bradycardia: markedly low heart rate requiring medical attention.
• Heart block: impairment of electrical conduction in the heart.
• Hypotension: dangerously low blood pressure causing fainting.
• Bronchospasm: narrowing of airways, particularly in patients with asthma.
• Allergic reactions: rash, swelling, or anaphylaxis.

Before prescribing Metoprolol Ratiopharm, clinicians should consider several safety measures.

• Monitor blood pressure: check regularly to ensure therapeutic control.
• Assess heart rate: watch for excessive slowing, especially in patients with conduction disorders.
• Use caution in asthma or COPD: β1‑selectivity may still affect bronchial tone.
• Adjust dose in renal or hepatic impairment: reduced clearance may increase drug levels.
• Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension or tachycardia.
• Store at room temperature: keep in the original packaging, protect from moisture and heat.

Metoprolol Ratiopharm can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Verapamil or diltiazem: combined use can cause profound bradycardia or heart block.
• Clonidine withdrawal: stopping clonidine while on metoprolol may precipitate severe hypertension.
• Other AV‑node blockers (e.g., digoxin): may lead to excessive slowing of cardiac conduction.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect.
• Diuretics: can enhance hypotensive response, requiring dose adjustment.
• Antidepressants (e.g., SSRIs): may increase plasma levels of metoprolol.
• Antidiabetic agents: beta‑blockade can mask hypoglycaemia symptoms.
• Calcium channel blockers (non‑diltiazem): may modestly increase bradycardia risk.